Emergency department visits for antiviral adverse events during the 2009 H1N1 influenza pandemic

Public Health Reports

Volumn 126, Issue 3, 2011, Pages 312-317

  Lovegrove, Maribeth C ^a   Shehab, Nadine ^a   Hales, Craig M ^b   Poneleit, Kathy ^c   Crane, Elizabeth ^c   Budnitz, Daniel S ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR; ANTIVIRUS AGENT;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; DIARRHEA; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EMERGENCY WARD; EPIDEMIC; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MUSCULOSKELETAL DISEASE; NAUSEA; PANDEMIC INFLUENZA; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY FUNCTION DISORDER; SCHOOL CHILD; SIDE EFFECT; TREATMENT RESPONSE; VOMITING; DRUG SURVEILLANCE PROGRAM; DRUG TOXICITY; EMERGENCY HEALTH SERVICE; HEALTH SURVEY; INFLUENZA; MIDDLE AGED; OUTPATIENT; UNITED STATES; UTILIZATION REVIEW; VIROLOGY;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTIVIRAL AGENTS; CHILD; DISEASE OUTBREAKS; DRUG TOXICITY; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OUTPATIENTS; POPULATION SURVEILLANCE; UNITED STATES;

EID: 79957836508     PISSN: 00333549     EISSN: 14682877     Source Type: Journal    
DOI: 10.1177/003335491112600303     Document Type: Article

References (17)

1. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360:2605-15.
2. Department of Health and Human Services (US). Determination that a public health emergency exists. April 2009 [cited 2009 Dec 23]. Available from: URL: http://www.hhs.gov/secretary/phe_swh1n1_april_2009.html
3. Update: influenza activity-United States, August 30, 2009-March 27, 2010, and composition of the 2010-11 influenza vaccine. MMWR Morb Mortal Wkly Rep 2010;59(14):423-30.
4. Update: influenza activity-United States, August 30-October 31, 2009. MMWR Morb Mortal Wkly Rep 2009;58(44):1236-41.
5. Centers for Disease Control and Prevention (US). Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season [cited 2009 Dec 23]. Available from: URL: http://www.cdc.gov/H1N1flu/recommendations.htm
6. Food and Drug Administration (US). Adverse Event Reporting System (AERS) [cited 2009 Dec 23]. Available from: URL: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm
7. Institute of Medicine. Antivirals for pandemic influenza: guidance on developing a distribution and dispensing program. Washington: National Academies Press; 2008.
8. Substance Abuse and Mental Health Services Administration, Office of Applied Studies (US). Drug Abuse Warning Network, 2006: national estimates of drug-related emergency department visits. DAWN Series D-30, DHHS Publication No. (SMA) 08-4339. Rockville (MD): SAMHSA; 2008.
9. Bousquet C, Lagier G, Lillo-Le Louët A, Le Beller C, Venot A, Jaulent MC. Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions. Drug Saf 2005;28:19-34.
10. SAS Institute, Inc. SAS®: Version 9.2 for Windows. Cary (NC): SAS Institute, Inc.; 2008.
11. CDC (US). BioSense [cited 2009 Dec 23]. Available from: URL: http://www.cdc.gov/biosense/index.html
12. Update: influenza activity-United States, April-August 2009. MMWR Morb Mortal Wkly Rep 2009;58(36):1009-12.
13. CDC (US). Fluview: a weekly influenza surveillance report prepared by the Influenza Division [cited 2009 Dec 23]. Available from: URL: http://www.cdc.gov/flu/weekly/weeklyarchives2009-2010/weekly50.htm
14. Khazeni N, Bravata DM, Holty JE, Uyeki TM, Stave CD, Gould MK. Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med 2009;151:464-73.
15. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009;339:b5106. doi: 10.1136/bmj.b5106.
16. Matheson NJ, Harnden AR, Perera R, Sheikh A, Symmonds-Abrahams M. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev 2007;(1):CD002744.
17. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006;296:1858-66.